Prospective Safety Evaluation of the Femtosecond Laser-Assisted Keratomileusis Procedure in Correcting Residual Ametropia in Patients After Deep Anterior Lamellar Keratoplasty

Dominika Janiszewska-Bil; Barbara Czarnota-Nowakowska; Katarzyna Krysik; Magdalena Mistarz; Dariusz Dobrowolski; Beniamin Oskar Grabarek; Anita Lyssek-boroń

doi:10.12659/MSM.939691

17 March 2023 : Clinical Research

Prospective Safety Evaluation of the Femtosecond Laser-Assisted Keratomileusis Procedure in Correcting Residual Ametropia in Patients After Deep Anterior Lamellar Keratoplasty

Dominika Janiszewska-Bil^123ABCDEF*, Barbara Czarnota-Nowakowska^4ABDE, Katarzyna Krysik^13E, Magdalena Mistarz^15E, Dariusz Dobrowolski^367CD, Beniamin Oskar Grabarek^15EF, Anita Lyssek-boroń^138CE

DOI: 10.12659/MSM.939691

Med Sci Monit 2023; 29:e939691

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Topical and general treatment scheme after deep anterior lamellar keratoplasty (DALK).

Chemical name	Drug form	Dosage
Dexamethasone sodium salt	Drops	5 times a day
Moxifloxacin hydrochloride	Drops	5 times a day
Cellulose acetate	Drops	7 times a day
Ciprofloxacin 500 mg	Pills	1 pill every 12 hours
Methylprednisolone acetate 4 mg	Pills	1 pill in the morning

Back to the Article

Prospective Safety Evaluation of the Femtosecond Laser-Assisted Keratomileusis Procedure in Correcting Residual Ametropia in Patients After Deep Anterior Lamellar Keratoplasty

Your Privacy